Moderna, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Moderna, Inc. (MRNA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $654.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-20
- Moderna, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2023-12-31 was $369.00M.
- Moderna, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2023-09-30 was $1.70B.
- Moderna, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2021-12-31 was $97.00M.
- Moderna, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2021-09-30 was $0.00.
- Moderna, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $654.00M, a 23.95% decline from fiscal 2024.
- Moderna, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $860.00M, a 58.43% decline from fiscal 2023.
- Moderna, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $2.07B, a 11394.44% increase from fiscal 2022.
- Moderna, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $18.00M, a 62.50% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $654.00M 10-K · filed 2026-02-20 | ||||
| 2024-12-31 | $860.00M 10-K · filed 2026-02-20 | ||||
| 2023-12-31 | $369.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.07B derived: sum of 2 quarters · filed 2026-02-20 | $2.07B 10-K · filed 2026-02-20 | ||
| 2023-09-30 | $1.70B 10-Q · filed 2023-11-03 | $1.70B 10-Q · filed 2023-11-03 | |||
| 2022-12-31 | $18.00M 10-K · filed 2025-02-21 | ||||
| 2021-12-31 | $97.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $97.00M derived: sum of 2 quarters · filed 2024-02-23 | $48.00M derived: sum of 3 quarters · filed 2024-02-23 | $48.00M 10-K · filed 2024-02-23 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$49.00M derived: sum of 2 quarters · filed 2021-11-04 | -$49.00M 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | -$49.00M 10-Q · filed 2021-08-05 | -$49.00M 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | -$49.00M 10-Q · filed 2021-05-06 | ||||
| 2020-12-31 | $352.00M 10-K · filed 2023-02-24 | $352.70M 10-K · filed 2021-02-26 | |||
| 2019-12-31 | $163.00M 10-K · filed 2022-02-25 | $162.50M 10-K · filed 2020-02-27 | |||
| 2018-12-31 | $109.60M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |